Eli Lilly
Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population
August 6, 2019Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma
New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …
Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data
July 31, 2019Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma
Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …
Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection
July 25, 2019Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma
Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …
US Judge blocks Trump administration law requiring pharma to include prices in TV ads
July 9, 2019Manufacturing and Production Amgen, Eli Lilly, MSD, TV ads, Trump, USA, court, pharma
A judge has blocked the Trump administration from enacting a law that would require pharmaceutical companies to include the prices …
Drugmakers sue Trump over prices in TV ads
June 17, 2019Sales and Marketing Amgen, Eli Lilly, HHS, MSD, Merck, Trump, pharma
Amgen, Eli Lilly and MSD have sued the Trump administration to try and block measures to force pharma companies to …
Eli Lilly’s heart drug underwhelms with REWIND trial
June 11, 2019Manufacturing and Production Eli Lilly, Trulicity, pharma
Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according …
Eli Lilly’s Emgality approved in the US for episodic cluster headache
June 5, 2019Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma
Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …
Japan’s health ministry warns of serious side effects of Lilly’s Verzenio
May 23, 2019Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma
Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …
Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population
May 13, 2019Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …
Top Ten most popular articles on Pharmafile.com this week!
May 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma
This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
May 8, 2019Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …
Top Ten most popular articles on Pharmafile.com this week!
May 3, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Gilead, autism, dementia, opioids, pharma
This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from …
Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
April 26, 2019Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment
March 13, 2019Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …
Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients
February 15, 2019Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …
